Treatment access and disparities in chemotherapy utilization among very elderly patients with metastatic NSCLC: A SEER-based quality of care analysis.
Abstract
185 Background: Equitable access to systemic therapy is a measurable indicator of quality oncologic care, yet very elderly patients with metastatic non-small cell lung cancer (NSCLC) remain undertreated and underrepresented in clinical trials. The evolution of targeted therapies and immune checkpoint inhibitors has reshaped treatment paradigms and may influence utilization patterns. We evaluated national patterns of chemotherapy receipt, treatment disparities, and associated survival outcomes in very elderly patients with metastatic NSCLC. Methods: Using SEER, we identified patients aged ≥80 years with metastatic lung adenocarcinoma or squamous cell carcinoma diagnosed from 2004 to 2022. Temporal trends in chemotherapy utilization were assessed across four periods—multivariable logistic regression identified independent predictors of chemotherapy receipt. Overall survival (OS) and cancer-specific survival (CSS) were assessed using Kaplan–Meier methods. Results: Among 31,445 patients, only 9,032 (28.7%) received chemotherapy, a modest increase from 25.1% (2004–2008) to 30.2% (2018–2022). Increasing age was associated with markedly lower treatment odds (age 85–89: OR 0.59; ≥90: OR 0.29; p<0.001). Black patients had lower odds of treatment compared with White patients (OR 0.90, p=0.042), while Asian/Pacific Islander patients had higher odds (OR 1.33, p<0.001). Widowed and unmarried patients demonstrated lower treatment receipt (OR 0.71 and 0.66; both p<0.001), and higher income independently predicted treatment utilization (OR 1.21, p<0.001). Squamous histology was associated with lower chemotherapy use (OR 0.77, p<0.001). Median OS was 10 versus 2 months among treated versus untreated patients (p<0.001). Conclusions: Fewer than one in three very elderly patients with metastatic NSCLC received chemotherapy, with substantial disparities associated with age, race, socioeconomic status, and social determinants of health. These findings identify persistent gaps in the delivery of equitable treatment and support implementing geriatric assessment, patient navigation, and individualized, goal-concordant treatment discussions to improve access to guideline-concordant care for older adults with advanced NSCLC. Predictors of chemotherapy receipt among older adults with metastatic NSCLC (N=31,445). Predictor Adjusted OR (95% CI) P 2018–2022 vs 2004–2008 1.31 (1.22–1.41) <0.001 Age 85–89 vs 80–84 0.59 (0.56–0.63) <0.001 Age ≥90 vs 80–84 0.29 (0.26–0.33) <0.001 Asian/Pacific Islander vs White 1.33 (1.23–1.43) <0.001 Black vs White 0.90 (0.81–1.00) 0.042 Widowed vs Married 0.71 (0.67–0.75) <0.001 Unmarried vs Married 0.66 (0.61–0.71) <0.001 Highest vs Lowest Income Quartile 1.21 (1.12–1.31) <0.001 Squamous vs Adenocarcinoma 0.77 (0.72–0.81) <0.001